^
Association details:
Biomarker:EGFR A763_Y764insFQEA
Cancer:Lung Adenocarcinoma
Drug:erlotinib (EGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors

Excerpt:
We further confirmed these findings using patient-derived lung adenocarcinoma cell lines. The EGFR-A763_Y764insFQEA-bearing BID007 cells were more sensitive to erlotinib, afatinib, and osimertinib…
DOI:
https://doi.org/10.1016/j.jtocrr.2020.100051